Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fuqing King Dnarmsa Spirulina is a China-based algae and nutraceutical company focused on the cultivation, processing, and export of spirulina- and chlorella-based products. The company appears to operate commercially rather than as a therapeutic drug developer, with offerings including spirulina powder, tablets, capsules, and related health-food ingredients. Available profiles describe the business as integrating algae cultivation, research, production, and sales, with multiple cultivation farms and an algae research institute. Its products are marketed into nutrition, health care, beauty, and food applications, with exports to China, Europe, the United States, and other regions. Based on the available evidence, it is best classified as a commercial nutraceutical and ingredient manufacturer rather than a biotech or pharmaceutical pipeline company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on King DnarmsaSpirulina.